ATAI Life Sciences BV (NASDAQ:ATAI) — Market Cap & Net Worth
Market Cap & Net Worth: ATAI Life Sciences BV (ATAI)
ATAI Life Sciences BV (NASDAQ:ATAI) has a market capitalization of $1.45 Billion ($1.45 Billion) as of August 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #7214 globally and #2199 in its home market, demonstrating a 0.14% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ATAI Life Sciences BV's stock price $7.18 by its total outstanding shares 368166674 (368.17 Million). See ATAI Life Sciences BV capital spending ratio to understand how much of operating cash flow is reinvested back into capital assets.
ATAI Life Sciences BV Market Cap History: 2021 to 2026
ATAI Life Sciences BV's market capitalization history from 2021 to 2026. Data shows change from $2.81 Billion to $2.64 Billion (-17.69% CAGR).
Index Memberships
ATAI Life Sciences BV is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.46 Trillion | 0.06% | #208 of 976 |
|
NASDAQ Composite
IXIC
|
$40.26 Trillion | 0.00% | #812 of 3165 |
Weight: ATAI Life Sciences BV's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
ATAI Life Sciences BV Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ATAI Life Sciences BV's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
368.26x
ATAI Life Sciences BV's market cap is 368.26 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $2.81 Billion | $20.38 Million | -$167.81 Million | 137.86x | N/A |
| 2022 | $979.32 Million | $233.00K | -$152.38 Million | 4203.10x | N/A |
| 2023 | $519.12 Million | $314.00K | -$40.22 Million | 1653.23x | N/A |
| 2024 | $489.66 Million | $308.00K | -$149.27 Million | 1589.81x | N/A |
| 2025 | $1.51 Billion | $4.09 Million | -$660.05 Million | 368.26x | N/A |
Competitor Companies of ATAI by Market Capitalization
Companies near ATAI Life Sciences BV in the global market cap rankings as of August 3, 2026.
Key companies related to ATAI Life Sciences BV by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #543 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $477.10 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $762.63 |
| #543 | Argen-X | BR:ARGX | $49.55 Billion | €745.00 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €222.90 |
ATAI Life Sciences BV Historical Marketcap From 2021 to 2026
Between 2021 and today, ATAI Life Sciences BV's market cap moved from $2.81 Billion to $ 2.64 Billion, with a yearly change of -17.69%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.64 Billion | +75.55% |
| 2025 | $1.51 Billion | +207.52% |
| 2024 | $489.66 Million | -5.67% |
| 2023 | $519.12 Million | -46.99% |
| 2022 | $979.32 Million | -65.14% |
| 2021 | $2.81 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 3rd, 2026 the market cap of ATAI Life Sciences BV was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.45 Billion USD |
| MoneyControl | $1.45 Billion USD |
| MarketWatch | $1.45 Billion USD |
| marketcap.company | $1.45 Billion USD |
| Reuters | $1.45 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ATAI Life Sciences BV
AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder… Read more